Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 24, 2023 06:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

New appointments bring therapeutic development expertise and proven leadership to support continued progress of Allarity’s multiple oncology clinical programs BOSTON (July 24, 2023) — Allarity...
July 06, 2023 06:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering

BOSTON, MA (July 6, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
July 05, 2023 09:45 ET | Source: Allarity Therapeutics, Inc.

Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients

Boston, MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
June 28, 2023 11:55 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Reverse Stock Split of Common Stock

- Common Stock Will Begin Trading on a Post-Split Adjusted Basis on June 29, 2023 Press ReleaseBOSTON, MA (June 28, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”),...
June 27, 2023 18:16 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split

Press Release BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
June 20, 2023 16:05 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders

Meeting adjourned to Friday, June 23, 2023 at 1:00 p.m. Eastern Time Press release BOSTON, MA (June 20, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a...
May 30, 2023 06:00 ET | Source: Allarity Therapeutics, Inc.

First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting

Phase 2 study evaluating the utility of a DRP® companion diagnostic for cisplatin supports its ability to predict drug response in certain breast cancer patients Boston, MA (May 30, 2023) —...
April 19, 2023 09:18 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering

Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering BOSTON, MA (April 19, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a...
April 11, 2023 07:00 ET | Source: Allarity Therapeutics, Inc.

Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting

FOR IMMEDIATE RELEASE Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting Poster presentation focused on a Phase 2 Clinical Study...
March 28, 2023 06:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies

Efforts underway to accelerate patient recruitment and amend protocols to improve patient outcomes. Interim data readouts for both studies anticipated in H2 2023. Press release BOSTON — March 28,...